Inventiva S.A. American Depository Shares (IVA) Stock Price

IVAStock

$4.69−16.55%52W

Market Cap$1.11B

P/E—

PEG Ratio—

Div yield—

Beta-0.47

IVA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-38.56%

Price vs S&P 500 (4W)0.89%

VGM Score27.81

Book Value / Share (Quarterly)$1.26

P/TBV (Annual)4.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-28.33%

Cash Flow / Share (Quarterly)$-0.50

Price vs S&P 500 (YTD)-7.04%

Net Profit Margin (TTM)-7899.55%

EPS (TTM)$-2.67

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$-2.67

Revenue Growth (5Y)64.51%

EPS (Annual)$-2.21

ROI (Annual)-67.94%

Net Profit Margin (5Y Avg)-2432.66%

Cash / Share (Quarterly)$1.39

Revenue Growth QoQ (YoY)-99.68%

ROA (Last FY)-141.93%

Revenue Growth TTM (YoY)-51.26%

EBITD / Share (TTM)$-0.86

ROE (5Y Avg)-66.60%

Operating Margin (TTM)-3145.51%

Cash Flow / Share (Annual)$-0.63

P/B Ratio21.42x

P/B Ratio (Quarterly)4.50x

Net Income / Employee (Annual)$-7,125,386

EV / Revenue (TTM)208.47x

Net Interest Coverage (TTM)-0.66x

ROA (TTM)-165.30%

EPS Incl Extra (Annual)$-2.21

Current Ratio (Annual)3.16x

Quick Ratio (Quarterly)3.11x

3-Month Avg Trading Volume0.34M

52-Week Price Return-16.55%

Revenue / Employee (TTM)$90,208

Tangible BV / Share (Quarterly)$1.24

P/S Ratio (Annual)217.37x

Asset Turnover (Annual)0.02x

52-Week High$7.24

Operating Margin (5Y Avg)-1301.07%

EPS Excl Extra (Annual)$-2.21

CapEx CAGR (5Y)-3.29%

Tangible BV CAGR (5Y)-5.66%

26-Week Price Return-27.31%

Quick Ratio (Annual)3.11x

13-Week Price Return-10.71%

Total Debt / Equity (Annual)0.76x

Current Ratio (Quarterly)3.16x

Enterprise Value$1.09B

Revenue / Share Growth (5Y)16.89%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-22.11%

Revenue / Employee (Annual)$90,208

Pretax Margin (Annual)-7891.26%

Cash / Share (Annual)$1.39

3-Month Return Std Dev64.61%

Net Income / Employee (TTM)$-7,125,386

ROE (Last FY)-119.35%

Net Interest Coverage (Annual)-0.60x

EPS Basic Excl Extra (Annual)$-2.21

Receivables Turnover (TTM)3.52x

Total Debt / Equity (Quarterly)0.76x

EPS Incl Extra (TTM)$-2.67

Receivables Turnover (Annual)3.52x

ROI (TTM)-99.63%

P/S Ratio (TTM)217.37x

Pretax Margin (5Y Avg)-2424.93%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$1.24

Price vs S&P 500 (52W)-34.86%

Year-to-Date Return3.55%

5-Day Price Return0.25%

EPS Normalized (Annual)$-2.21

ROA (5Y Avg)-108.60%

Net Profit Margin (Annual)-7899.55%

Month-to-Date Return7.50%

Cash Flow / Share (TTM)$-2.18

EBITD / Share (Annual)$-0.86

Operating Margin (Annual)-3145.51%

LT Debt / Equity (Annual)0.56x

ROI (5Y Avg)-54.61%

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$-2.67

P/TBV (Quarterly)4.56x

P/B Ratio (Annual)4.50x

Pretax Margin (TTM)-7891.26%

Book Value / Share (Annual)$1.26

Price vs S&P 500 (13W)-13.50%

Beta-0.47x

Revenue / Share (TTM)$0.02

ROE (TTM)-145.38%

52-Week Low$3.36

vGradeF

gGradeD

mGradeD

vgmGradeD

IVA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.44

4.41

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
IVAInventiva S.A. American Depository Shares	F	D	D	$4.69
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Inventiva S.A. American Depository Shares

Inventiva SA is a French biopharmaceutical company developing drug candidates targeting nuclear receptors and epigenetic pathways. Its lead program, lanifibranor, is being advanced for non-alcoholic steatohepatitis (NASH), a disease with no currently approved treatments, representing a significant commercial opportunity. The company maintains a pre-clinical pipeline in oncology, fibrosis, and rare diseases, and generates revenue through research partnerships with major pharmaceutical partners including AbbVie and BI.